Facebook
Twitter
LinkedIn
ForwardPulse - Middle Management: Exploring Treatment Options in HFmrEF
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
In recent years, heart failure with mid-range ejection fraction (HFmrEF) was introduced as a new classification of heart failure. HFmrEF is defined as having a left ventricular ejection fraction (LVEF) between 40 and 49%. Multiple studies surrounding the chronic treatment of heart failure have been conducted in patients with HFrEF and HFpEF. However, there remains a gap in knowledge for patients who fall within the middle category of HFmrEF. Due to this lack of evidence, the AHA/ACC/HFSA and ESC guidelines provide weaker recommendations for guideline-directed medical therapy (GDMT) in this patient population. This presentation will review the available literature surrounding the treatment of HFmrEF and assess whether it may be beneficial in this patient population
Target Audience
Pharmacist
Learning Objectives
- Explain current guideline recommendations for the treatment of HFmrEF
- Identify available literature surrounding the treatment of HFmrEF
- Discuss current literature for the treatment of HFmrEF, given a patient case
Additional Information
| Attachment | Size |
|---|---|
 Audience Disclosure slide_HM.pptx | 913.79 KB |
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
In recent years, heart failure with mid-range ejection fraction (HFmrEF) was introduced as a new classification of heart failure. HFmrEF is defined as having a left ventricular ejection fraction (LVEF) between 40 and 49%. Multiple studies surrounding the chronic treatment of heart failure have been conducted in patients with HFrEF and HFpEF. However, there remains a gap in knowledge for patients who fall within the middle category of HFmrEF. Due to this lack of evidence, the AHA/ACC/HFSA and ESC guidelines provide weaker recommendations for guideline-directed medical therapy (GDMT) in this patient population. This presentation will review the available literature surrounding the treatment of HFmrEF and assess whether it may be beneficial in this patient population
Hannah Madara, PharmD
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.